Elicio Therapeutics

A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).    The data produced by Elicio Therapeutics Inc. (NASDAQ: ELTX) demonstrates how Elicio’s proprietary...

A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear.  As part of its randomized phase 2 AMPLIFY-7P study of ELI-002 7P as an adjuvant monotherapy in Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma (PDAC), Elicio Therapeutics Inc. (NYSE: ELTX...

Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the second and third leading causes of cancer death, respectively. Pancreatic and colorectal cancers are often Kirsten rat sarcoma (KRAS) mutated and are incurable when tumor DNA or protein persists or recurs after curative...

Elicio Therapeutics Inc. (NYSE: ELTX) is using precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. Founded in 2011, the company has developed an innovative pipeline of cancer immunotherapies addressing...

An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease.  With its proprietary...

Founded in 2011, Elicio Therapeutics Inc. (NASDAQ: ELTX) strives to use precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors.  Elicio’s proprietary Amphiphile or “AMP” platform...